Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,089 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Brain-wide functional connectivity of face patch neurons during rest.
Zaldivar D, Koyano KW, Ye FQ, Godlove DC, Park SH, Russ BE, Bhik-Ghanie R, Leopold DA. Zaldivar D, et al. Among authors: park sh. Proc Natl Acad Sci U S A. 2022 Sep 6;119(36):e2206559119. doi: 10.1073/pnas.2206559119. Epub 2022 Aug 31. Proc Natl Acad Sci U S A. 2022. PMID: 36044550 Free PMC article.
Studying the visual brain in its natural rhythm.
Leopold DA, Park SH. Leopold DA, et al. Among authors: park sh. Neuroimage. 2020 Aug 1;216:116790. doi: 10.1016/j.neuroimage.2020.116790. Epub 2020 Apr 8. Neuroimage. 2020. PMID: 32278093 Free PMC article. Review.
Calcium-permeable AMPA receptors govern PV neuron feature selectivity.
Hong I, Kim J, Hainmueller T, Kim DW, Keijser J, Johnson RC, Park SH, Limjunyawong N, Yang Z, Cheon D, Hwang T, Agarwal A, Cholvin T, Krienen FM, McCarroll SA, Dong X, Leopold DA, Blackshaw S, Sprekeler H, Bergles DE, Bartos M, Brown SP, Huganir RL. Hong I, et al. Among authors: park sh. Nature. 2024 Nov;635(8038):398-405. doi: 10.1038/s41586-024-08027-2. Epub 2024 Oct 2. Nature. 2024. PMID: 39358515 Free PMC article.
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM, Crandall W, Durand F, Hon E, Lin Z, Lopes MU, Morris N, Protic M, Carlier H, Sands BE; VIVID Study Group. Ferrante M, et al. Lancet. 2024 Nov 21:S0140-6736(24)01762-8. doi: 10.1016/S0140-6736(24)01762-8. Online ahead of print. Lancet. 2024. PMID: 39581202
11,089 results
You have reached the last available page of results. Please see the User Guide for more information.